Mabion Past Earnings Performance
Past criteria checks 1/6
Mabion has been growing earnings at an average annual rate of 62.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 54.3% per year. Mabion's return on equity is 7.9%, and it has net margins of 9.2%.
Key information
62.3%
Earnings growth rate
63.1%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | 54.3% |
| Return on equity | 7.9% |
| Net Margin | 9.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Some May Be Optimistic About Mabion's (WSE:MAB) Earnings
Nov 06
Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 24Recent updates
Revenues Working Against Mabion S.A.'s (WSE:MAB) Share Price Following 29% Dive
Dec 22Some May Be Optimistic About Mabion's (WSE:MAB) Earnings
Nov 06Investors Don't See Light At End Of Mabion S.A.'s (WSE:MAB) Tunnel And Push Stock Down 30%
Nov 05Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 24Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth
Nov 28Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts
Jun 02Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?
Jul 09Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News
Jun 04Is Mabion (WSE:MAB) Using Too Much Debt?
Dec 22Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate
Sep 11How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?
Feb 24Revenue & Expenses Breakdown
How Mabion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 111 | 10 | 53 | 2 |
| 30 Jun 24 | 140 | 37 | 49 | 3 |
| 31 Mar 24 | 146 | 42 | 42 | 5 |
| 31 Dec 23 | 152 | 41 | 40 | 6 |
| 30 Sep 23 | 148 | 58 | 39 | 8 |
| 30 Jun 23 | 157 | 42 | 35 | 14 |
| 31 Mar 23 | 165 | 32 | 31 | 15 |
| 31 Dec 22 | 164 | 23 | 29 | 15 |
| 30 Sep 22 | 156 | 45 | 34 | 8 |
| 30 Jun 22 | 117 | 34 | 34 | 9 |
| 31 Mar 22 | 75 | 26 | 32 | 8 |
| 31 Dec 21 | 36 | 2 | 30 | 14 |
| 30 Sep 21 | 2 | -51 | 21 | 28 |
| 30 Jun 21 | 2 | -45 | 20 | 24 |
| 31 Mar 21 | 0 | -53 | 20 | 30 |
| 31 Dec 20 | 0 | -56 | 19 | 34 |
| 30 Sep 20 | 0 | -55 | 17 | 36 |
| 30 Jun 20 | 0 | -63 | 18 | 40 |
| 31 Mar 20 | 0 | -69 | 21 | 43 |
| 31 Dec 19 | 0 | -64 | 21 | 41 |
| 30 Sep 19 | 0 | -65 | 22 | 40 |
| 30 Jun 19 | 0 | -59 | 21 | 39 |
| 31 Mar 19 | 0 | -70 | 20 | 45 |
| 31 Dec 18 | 0 | -69 | 20 | 45 |
| 30 Sep 18 | 0 | -72 | 23 | 48 |
| 30 Jun 18 | 0 | -74 | 23 | 49 |
| 31 Mar 18 | 0 | -59 | 22 | 41 |
| 31 Dec 17 | 0 | -58 | 21 | 43 |
| 30 Sep 17 | 0 | -56 | 18 | 43 |
| 30 Jun 17 | 0 | -57 | 16 | 47 |
| 31 Mar 17 | 0 | -59 | 15 | 47 |
| 31 Dec 16 | 0 | -56 | 13 | 44 |
| 30 Sep 16 | 0 | -77 | 11 | 71 |
| 30 Jun 16 | 0 | -65 | 9 | 59 |
| 31 Mar 16 | 3 | -51 | 8 | 48 |
| 31 Dec 15 | 3 | -43 | 5 | 40 |
| 30 Sep 15 | 3 | -6 | 4 | 0 |
| 30 Jun 15 | 3 | -5 | 3 | 0 |
| 31 Mar 15 | 1 | -5 | 2 | 0 |
| 31 Dec 14 | 1 | -4 | 1 | 0 |
| 30 Sep 14 | 1 | -4 | 4 | 0 |
| 30 Jun 14 | 0 | -4 | 4 | 0 |
| 31 Mar 14 | 0 | -4 | 4 | 0 |
| 31 Dec 13 | 0 | -4 | 4 | 0 |
Quality Earnings: MAB has a large one-off loss of PLN14.1M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: MAB's current net profit margins (9.2%) are lower than last year (39.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MAB has become profitable over the past 5 years, growing earnings by 62.3% per year.
Accelerating Growth: MAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MAB had negative earnings growth (-82.4%) over the past year, making it difficult to compare to the Biotechs industry average (-18.2%).
Return on Equity
High ROE: MAB's Return on Equity (7.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 04:25 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mabion S.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Pawel Sugalski | ING Groep NV |